




**World Dementia
Council** Leading the Global Action
Against Dementia


Global dialogue on data sharing for dementia research: Agenda and participants

The dementia landscape project

9 June 2021



Logistics and agenda



Wednesday 9 June 2021


Virtual meeting

08:00 PDT San Francisco
10:00 CDT Chicago
11:00 EDT New York
16:00 BST London
17:00 CEST Central Europe



Section	Speaker(s)
Welcome	Lenny Shallcross
Opening remarks	Dr Lara Mangravite
Opening presentations	Chaired by Dr Lara Mangravite Professor Andrew Morris Dr Angela Bradshaw Dr Suzana Petanceska
Group conversation	Introduced and moderated by Dr Tetsu Maruyama
Closing perspectives	Dr Lara Mangravite
Closing thanks	Lenny Shallcross

Co-chairs



Dr Lara Mangravite

Lara Mangravite, PhD, is President of Sage Bionetworks. This organization is focused on the development and implementation of practices for large-scale collaborative biomedical research. Our work is centered on new approaches to scientific process that use open systems to enable community-based research regarding complex biomedical problems. Previously, Dr. Mangravite served as Director of the Systems Biology research group at Sage Bionetworks where she focused on the application of collaborative approaches to advance understanding of disease biology and treatment outcomes at a systems level with the overriding goal of improving clinical care. Dr. Mangravite obtained a BS in Physics from the Pennsylvania State University and a PhD in Pharmaceutical Chemistry from the University of California, San Francisco. She completed a postdoctoral fellowship in cardiovascular pharmacogenomics at the Children’s Hospital Oakland Research Institute.




Dr Tetsu Maruyama

Tetsu Maruyama is the Executive Director of the ADDI, where he has the pleasure of working with an exceptional team to enable data relevant to Alzheimer’s and related dementias to reach their full potential. Prior to joining ADDI, Tetsu was the Chief Scientific Officer at the Dementia Discovery Fund, a unique venture capital fund focusing a total investment of \$350 million on creating new treatment paradigms for dementia. Before that he was head of Drug Discovery for Takeda Pharmaceuticals in Japan, after leading the GlaxoSmithKline Centre for Cognitive and Neurodegenerative Disorders in Singapore. He began his industry career at Merck Sharp and Dohme’s Neuroscience Research Center in the UK, after 15 years as an academic neuroscientist at Cardiff University and the University of Minnesota.



Speakers



Dr Angela Bradshaw


Dr. Angela Bradshaw is a Project Officer at Alzheimer Europe, an umbrella organisation of national Alzheimer's Associations with 39 members across 35 European countries. Alzheimer Europe aims to change perceptions, practice and policy, promoting a rights-based approach to dementia and working to make dementia a European priority. Angela collaborates on several EU-funded projects involving AI and health data, co-authoring the recent policy report "Data sharing in dementia research – the EU landscape". She obtained her PhD in vascular biology at the University of Cambridge, and worked as a lecturer at the University of Glasgow prior to joining Alzheimer Europe.



Professor Andrew Morris

Professor Andrew Morris became the inaugural Director of Health Data Research UK in August 2017. He is seconded from his position as Professor of Medicine, and Vice Principal of Data Science at the University of Edinburgh, having taken up position in August 2014. Prior to this Andrew was Dean of Medicine at the University of Dundee. Andrew was Chief Scientist at the Scottish Government Health Directorate (2012-2017) and has served and chaired numerous national and international grant committees and Governmental bodies. His research interests span informatics and chronic diseases.





Dr Suzana Petanceska


Dr Petanceska joined the National Institute on Aging in 2005, as a program director in the Division of Neuroscience. During her tenure at the NIA she has been overseeing and developing a number of research portfolios and programs in basic and translational research for Alzheimer's disease. She has been instrumental for the development of NIA's AD Translational Research program, the Epigenomics of AD portfolio and the Accelerated Medicines Partnership for AD (AMP AD) – Target Discovery and Preclinical Validation Project. Since 2012 she has been leading a number of NIA's strategic planning activities related to achieving the research goal of the National Plan to Address Alzheimer's: to prevent and treat AD by 2025.



Lenny Shallcross

Lenny Shallcross is executive director at the World Dementia Council. Prior to that he was Head of Community Engagement leading programmes across the UK to establish Dementia Friendly Communities. This includes the Dementia Friends programme which is the biggest health social movement campaign delivered by 10,000 volunteers that have recruited 2 million individuals through a community, digital and corporate offer. Before working for Alzheimer's Society he worked in the UK government as a political adviser at the Department for Culture, Media and Sport and the Department of Health, as well as working in Parliament and for the Labour Party.





Discussion participants



Professor Sandrine Andrieu

Professor of public health, chair of the clinical epidemiology and public health department at the Toulouse University Hospital


Sandrine Andrieu (M.D, PhD) is professor of public health, chair of the clinical epidemiology and public health department at the Toulouse University Hospital and adjunct professor at the University New Mexico (USA). Since 2009, she's responsible of aging research team in the center for Epidemiology and research in population health. She served as director of the research center for Epidemiology and research in population health (UMR1027 INSERM University Paul Sabatier) from 2011 to 2020. She has published more than 250 international papers and book chapters in the field of aging. She is involved in large prevention studies in the field of neuro-degenerative disease (GuidAge, MAPT) and in European projects (HATICE study, MIND-AD, PRODEMOS study). Her main topic of research is Alzheimer's disease and prevention of age-related loss of functions, and healthy aging. She's past-president of the French National Society of Geriatrics and Gerontology.



Dr Junaid Bajwa

Chief Medical Scientist at Microsoft Research

Dr. Junaid is a practicing physician in the NHS and is also the Chief Medical Scientist at Microsoft Research. He also serves as a Non-Executive Director at University College London Hospitals NHS Foundation Trust. He was previously the Global Lead for Strategic Alliances and Solutions for the Global Digital Centre of Excellence at Merck Sharp & Dohme (Merck & Co), where he helped shape their global digital strategy. Junaid also has experience in the academic world where he is a Clinical Associate Professor at University College London (UCL), and a Visiting Scientist at the Harvard School of Public Health. Over the past 15 years, Junaid has worked across primary care, secondary care, and public health settings in addition to acting as a payer, and policy maker within the UK, where he specialised in informatics, digital transformation, and leadership. He has also acted as a consultant for health care systems across the US, Australia, New Zealand, Singapore, the Middle East, and Europe.



Professor Howard Bergman

Professor of Family Medicine, Medicine (Geriatrics), and Oncology, McGill University


Dr Howard Bergman is Professor of Family Medicine, Medicine (Geriatrics), and Oncology, and Assistant Dean, International Affairs, Faculty of Medicine, McGill University. In 2009, at the request of the Quebec Minister of Health, he authored the Quebec Alzheimer Plan and is presently working with the Quebec ministry of health and social services on its implementation. He co-created and co-leads with Professor Isabelle Vedel, the Canadian team for healthcare services/system improvement in dementia care (ROSA research team). In 2018-19, he chaired the Canadian Academy of Health Sciences Panel of 6 experts for the Assessment of Evidence and Best Practices for the development of a Canadian Dementia Strategy, assembled at the request of Public Health Agency of Canada.



Niranjn Bose

Managing Director of Health and Life Sciences, Gates Ventures

Niranjn Bose is the Managing Director of Health and Life Sciences at Gates Ventures, where he serves as the Science Advisor to Mr. Bill Gates. Prior to this, he was the Chief of Staff to the President of the Global Health Program at the Bill & Melinda Gates Foundation. He was with the Gates Foundation from 2007 through 2014, which included a few years with their Enterics and Diarrheal Diseases (EDD) program strategy team, where he was responsible for managing a portfolio of investments, which included clinical development of enteric vaccines (rotavirus, cholera, enterotoxigenic E coli and shigella). Prior to joining the Bill & Melinda Gates Foundation, he was with Strategic Decisions Group (and SDG Life Sciences), where he was a Senior Consultant and assisted clients in the pharmaceutical and biotechnology industries with strategy development, company valuations, portfolio management frameworks, revenue forecasting, and competitive assessments. Niranjn holds a Ph.D. in biochemistry from Dartmouth College and an MS in biological sciences and BS in pharmaceutical sciences from Birla Institute of Technology and Science, Pilani, India. He also received the Business Bridge Diploma from the Tuck School of Business at Dartmouth.



Liz Brandt

Co-founder and CEO
of Ctrl-Shift


Liz Brandt is co-founder and CEO of Ctrl-Shift, her career has spanned 20+ years of business consultancy across numerous sectors. She currently advises a number of global clients including Facebook, O2, the BBC, and Suncorp, helping them to develop and future-proof their digital products and services. Her career has spanned multiple disciplines including consultancy, digital media, customer service design and strategic marketing. After twelve years with Barclays, Liz moved to the Systems Integrator company Logica, heading up their Sales and Marketing and the development and running of their international CRM business, after which she has founded several companies, including a mobile CRM company, Zishi, and Digital Public, a public sector consultancy developing a consumer-centric digital media service for government. Since its launch, Ctrl-Shift has been at the forefront of understanding, explaining and shaping the Personal Information Economy(PIE), it has pioneered Me2B digital services and Personal Information Services (PIMS) and remains at the forefront of strategic business consulting in the PIE market.



Dr Rosa Canet-Aviles

Lead Strategic
Alliances and
Collaborations, Eisai
Center for Genetics
Guided Dementia
Discovery

Rosa brings nearly two decades of experience developing and leading multi-stakeholder initiatives across biopharma, government and nonprofit organizations. In her previous role as the Director of Neuroscience Research Partnerships at the Foundation for the National Institutes of Health (FNIH), Rosa was responsible for the development and management of the Neuroscience Research Partnership portfolio of projects and programs that includes: the Accelerating Medicines Partnership (AMP) for Alzheimer’s Disease (AMP-AD), AMP Parkinson’s Disease (AMP-PD), AMP Schizophrenia (AMP SCZ), the Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3) and the Biomarkers Consortium Neuroscience Steering Committee (BC NSC). Rosa managed different teams in coordination with NIH, FDA, non-profit organizations and industry leaders. Rosa earned her PhD degree in neuroscience from the School of Medicine at Leeds University, UK. She also holds a BS in organic chemistry from the Central University of Barcelona.



Dr Maria Carrillo

Chief Scientific
Officer, Alzheimer's
Association


Maria Carrillo is chief scientific officer at the Alzheimer's Association (US), setting the strategic vision for the Association's global research program. Dr Carrillo has published extensively on early diagnosis and biomarker standardization efforts, as well as on the global challenges to progress for research in Alzheimer's and dementia. She is a co-author of the "Appropriate Use Criteria for Amyloid Imaging," published by the Society of Nuclear Medicine and Molecular Imaging and the Alzheimer's Association. Dr Carrillo earned her PhD from Northwestern University's Institute for Neuroscience and completed a postdoctoral fellowship focused on Alzheimer's brain imaging and risk factors at Rush University Medical Center in Chicago.



Dr Rodrigo Cataldi

Consultant for
the World Health
Organization (WHO)

Rodrigo Cataldi is a consultant for the World Health Organization (WHO) in the Brain Health Unit. He has a background in pharmacy with several years of experience working low-income settings in South America in the areas of public health, disease diagnostics and treatment. Rodrigo has a PhD from the University of Cambridge where he studied the molecular mechanisms underlying neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD). Before joining WHO, he has also worked as a consultant and senior scientist in the private sector on the development of therapeutics and diagnostic tools for AD, PD, cancer and type-2 diabetes.



Hannah Churchill

Research
Communications
Manager, Alzheimer's
Society (UK)


Hannah Churchill joined Alzheimer's Society in 2018; As Research Communications Manager, Hannah is dedicated to communicating the impact of Alzheimer's Society funded research as well as key developments from the wider dementia research community with people affected by dementia, our donors and supporters and, through channels such as mainstream media, to the wider world. Hannah also plays a critical role in our work to hold the government to account on their commitments to drive dementia research forward; working with other teams across research to provide our influencing work with a solid foundation of research evidence, emotive storytelling, and transparent data. Prior to joining Alzheimer's Society, Hannah worked in research communications at Parkinson's UK after graduating with a degree in Physiological Sciences from the University of Bristol.



Dr Fleur de Crespigny

Head of the Dementia
Unit at the Australian
Institute of Health and
Welfare

Fleur is the Head of the Dementia Unit at the Australian Institute of Health and Welfare. Her team was established in 2019 to address a major gap in national data, monitoring and reporting of dementia in Australia and to establish a long term, comprehensive monitoring program. As well as publishing the latest dementia-related statistics based on national health and aged care administrative data and national surveys, the team is undertaking a range of data improvement and methodological development projects, including through partnerships with academics in the field. Particular foci are improving the accuracy of dementia prevalence estimates for Australia, data linkage projects and developing primary care data (from GPs and specialists) for reporting on dementia. Fleur has a PhD in evolutionary biology and after a short academic career, joined the Australian Public Service in 2008. Over the last decade she has led teams producing a wide range of national health-related statistics.



Professor Bart De Strooper

Director, UK Dementia Research Institute, Professor and VIB researcher, KU Leuven, Belgium and UCL, London


Bart De Strooper, MD, PhD is director of the Dementia research Institute of the UK and professor of molecular medicine at the VIB Centre for Brain and Disease research University of Leuven and Professor at University College London. His scientific work is focused on the understanding of the fundamental mechanisms that underlie Alzheimer's and Parkinson's disease. His major finding is the identification of gamma-secretase and its role in the proteolysis of the amyloid precursor protein and in Notch signaling, for which he received the Brain Prize 2018 together with Hardy, Goedert and Haass. Recently he has reoriented his work to the understanding of the cellular phase of Alzheimer's disease. His aim is to understand the mechanisms of resilience that make that some people survive into very old age with the biochemical signs of Alzheimer's Disease but without the symptoms of dementia. He has published close to 400 papers with h-index of 121 and is recognized as highly cited researcher 2018, 2019 and 2020 (Clarivate, Web of Science Group). Expertscape considers him World Expert in Alzheimer's disease (no 8 worldwide), Presenilins (no 1 worldwide) and Amyloid beta-Peptides (no 4 worldwide).



Dave Evans

President and CEO, Clinical Data Interchange Standards Consortium (CDISC)

Dave Evans is recognized industry-wide as a leading technology visionary for developing and implementing complex process and system solutions and as an expert in the areas of information standards, regulatory compliance and quality governance. He was the architect and developer of the first electronic drug submission to the FDA in 1985 and has been responsible for more than 100 electronic regulatory submissions and complex clinical data warehouse systems. He brings over 40 years' experience to CDISC, serving in various executive-level positions in software development, clinical research, regulatory and healthcare industries. Most recently, he was the Global Head of Quality Governance and Regulatory Compliance for Accenture Life Sciences. Prior to that, he was CIO of Octagon Research Solutions and co-founder of Premier Research and Research Data Corporation. He has also served on the CDISC Board and has chaired the CDISC Advisory Council.



Professor Alan Evans

Professor of Neurology and Psychiatry, McGill University


Alan Evans is James McGill Professor of Neurology and Psychiatry at McGill University. He is Scientific Director of McGill's "Healthy Brains for Healthy Lives" initiative and the Canadian Open Neuroscience Platform. He is co-Director of the Ludmer Centre for Neuroinformatics and Mental Health, using high-performance computing to integrate imaging, behavior, genetics data in research into neurodegeneration and neurodevelopment. He has 673 publications (Google Scholar h-index=199). In 2014, he received the national Margolese Human Brain Disorders Prize and is a Highly Cited Scientist (163,014 citations ; top 1%) for Neuroscience and Behavior. He is a Fellow of the Royal Society of Canada and 2017 Chair of the Organization for Human Brain Mapping. In 2016, he received the Wilder Penfield Prix du Québec. In 2017, he was awarded the Senate of Canada 150 Medal, ranked #6 in its list of ten most influential brain scientists of the modern era by Science magazine. In 2018, he was awarded the Heinz Lehmann Prize in Neuropsychopharmacology and the Victor Dahdaleh Chair in Neurosciences. He was awarded the OHBM Glass Brain Award in 2019 and the Izaak Walton Killam Prize in Health Sciences in 2020, both for lifetime achievement.



Rhonda Facile

Vice President,
Development
Opportunities, Clinical
Data Interchange
Standards Consortium
(CDISC)

With over 30 years of experience in global clinical development and standards development, I work with global stakeholders, including regulatory authorities, pharma, vendors, academics and partner SDOs to build collaborative initiatives and pathways that extend and connect the CDISC standards with the goal of getting treatments to patients that need them.



Phyllis Ferrell

Global Head of External Engagement for Alzheimer's Disease and Neurodegeneration, Eli Lilly & Company


Phyllis Ferrell is the Global Head of External Engagement for Alzheimer's disease and Neurodegeneration at Eli Lilly & Company, where she previously served as the leader of the Global Alzheimer's disease development team. Ferrell's most recent prior position was Vice President of the Chief Commercial Services Officer for Eli Lilly and Company. Ferrell has been with Lilly for more than 25 years and has held many leadership roles throughout the organization. She has led efforts in medical affairs, medical development, commercial capabilities, sales, marketing, recruiting, business development, strategy, transformation, Six Sigma, and corporate financial planning. Ferrell received a Bachelor of Arts degree in economics and management with minors in computational mathematics and Asian studies from DePauw University. She graduated Phi Beta Kappa and with Magna Cum Laude honors in 1994. She received an MBA in general management and a certificate in public management from the Stanford University Graduate School of Business in 2001 and graduated with both Arjay Miller Scholar honors and as the Arbuckle Award recipient.



Dr Tatiana Foroud

Executive associate dean for Research Affairs at Indiana University School of Medicine and chair of the Department of Medical and Molecular Genetic

Dr. Tatiana Foroud is executive associate dean for Research Affairs at Indiana University School of Medicine and chair of the Department of Medical and Molecular Genetics. She is also executive vice president of Academic Affairs for Clinical Research at IU Health. Dr. Foroud is a statistical geneticist and leader in dementia research. She runs the NIH-designated repository for blood, DNA, tissue and other samples collected from patients throughout the country with Alzheimer's disease. Dr. Foroud's research is funded by the NIH and is focused on the identification of genes and genetic variants contributing to a range of neurodegenerative disorders, such as Alzheimer disease and Parkinson disease, as well as alcohol use disorders. She is also the principal investigator of multiple NIH and foundation supported biorepositories that lead efforts to identify biomarkers of Parkinson disease and Alzheimer disease. She is also the Scientific Director of the Indiana Biobank.



Professor John Gallacher

Professor of Cognitive Health, Oxford University


John Gallacher is Professor of Cognitive Health at Oxford University and Director of Dementias Platform UK, a MRC-funded public-private partnership focused on accelerating research into the early detection and treatment of dementia. An expert on brain health and the use of big data in medical research, Professor Gallacher holds a visiting professorship at Imperial College London and an honorary professorship at the University of Hong Kong. He is the Principal Investigator for the Caerphilly Prospective Study and a member of the UK Biobank steering group, leading on cognitive and psychological assessment.



Franca Gatto

Director of the Aging, Seniors and Dementia Division in the Centre for Health Promotion at the Public Health Agency of Canada

Franca Gatto is the Director of the Aging, Seniors and Dementia Division in the Centre for Health Promotion at the Public Health Agency of Canada, a position she has held since September 2017. Franca works with stakeholder organizations and provincial and territorial governments across Canada, and is the federal government focal point for health issues affecting Canada's older adult population. Through federal investments, partnerships and policy leadership, the Division of Aging, Seniors and Dementia seeks to promote healthy aging in the areas of dementia, injury prevention, and mental health. Franca and her team is responsible for the development of Canada's first national dementia strategy, A Dementia Strategy for Canada: Together We Aspire, launched in 2019. Along with her team she is spearheading the implementation of the national dementia strategy and is administering federal investments of \$70M over five years to support key components of the strategy. Prior to joining the Public Health Agency, Franca gained over 25 years of experience in providing strategic policy and communications advice to decision-makers in the federal Health Portfolio, primarily at Health Canada. Franca holds a Master of Business Administration from the University of Ottawa and a Bachelor of Public Relations from Mount Saint Vincent University in Halifax, Nova Scotia



Jean Georges

Executive Director,
Alzheimer Europe


Jean Georges is the Executive Director of Alzheimer Europe, a position he has held since November 1996. Mr Georges' role at Alzheimer Europe includes providing support for the Board, liaising with members or other European umbrella organisations, as well as managing of personnel, financial matters and overall project management of the various projects run by the organisation. Mr Georges has co-authored and contributed to several academic papers within the field of dementia and Alzheimer's. He has served as the Principal Investigator for Alzheimer Europe in projects supported by IMI (Innovative Medicines Initiative) and the European Union's Research and Innovation Funding Programmes: FP7 and Horizon2020. Prior to joining Alzheimer Europe, he served as a Parliamentary Assistant for members of the Luxembourg and European Parliaments and worked as a journalist in the European and International department of the Luxembourg newspaper "Tageblatt". Mr Georges earned his Bachelor's degree in English and European literature in 1986 from the University of Essex in the United Kingdom.



Professor Richard Gold

Founding Director
and current director,
Centre for Intellectual
Property Policy

Richard Gold was the founding Director and current director of the Centre for Intellectual Property Policy. He teaches in the area of intellectual property, international intellectual property, comparative intellectual property, innovation policy and intellectual property management. His research generally focuses on the life sciences. Professor Gold has provided advice to Health Canada, Industry Canada, the Canadian Biotechnology Advisory Committee, the Ontario Ministry of Health and Long-Term Care, the Organisation for Economic Cooperation and Development (where he was the lead author of the OECD Guidelines on the Licensing of Genetic Inventions and a report on Collaborative Mechanisms in Life Science Intellectual Property), the World Health Organization, the World Intellectual Property Organization and UNITAID.



Dr Magali Haas

CEO and President,
Cohen Veterans
Bioscience


Dr. Haas is Chair, CEO and President of Cohen Veterans Bioscience, a non-profit brain research organization based in New York City whose mission is to fast-track diagnostics and therapeutics to advance precision brain health. Magali has over 15 years of pharmaceutical executive experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in early & late stage neuroscience clinical development, translational medicine, diagnostics and integrative solutions. To pioneer new approaches for precision therapeutics for brain health, she founded Orion Bionetworks in 2012, which was transformed to Cohen Veterans Bioscience in 2015, while also serving as founding Chief Science and Technology Officer for One Mind for Research. She serves on several advisory boards including Alto Neurosciences, Partnership for Assessment and Accreditation of Scientific Practice, VirtualBrainCloud, Krembil Centre for Neuroinformatics and IMEC for nanoelectronics. Magali earned her BS in bioengineering from the University of Pennsylvania, an MS in biomedical engineering from Rutgers University, and her MD and PhD in neuroscience with distinction from Albert Einstein College of Medicine.



Professor Jens Habermann

Director General,
BBMRI-ERIC


Professor Jens K. Habermann, M.D., PH.D., is Director General of BBMRI-ERIC (Biobanking and Biomolecular Resources Research Infrastructure – European Research Infrastructure Consortium) since September 2020. He is on leave of absence from the University of Lübeck as Head of the Section of Translational Surgical Oncology and Biobanking and as Head of ICB-L (Interdisciplinary Center for Biobanking-Lübeck). He obtained his M.D. training at the Medical University of Lübeck (Lübeck, Germany), received his Ph.D. at the Cancer Center Karolinska, Karolinska Institute (Stockholm, Sweden) and a Postdoctoral Fellowship at the National Cancer Institute, NIH (Bethesda, USA). As board certified specialist in human genetics, Prof. Habermann combines clinics, biobanking, and translational (cancer) research to optimize precision medicine.



Dr Sean Hill

Director of the Krembil Centre for Neuroinformatics at the Centre for Addiction and Mental Health in Toronto, Canada


Dr. Sean Hill is inaugural Director of the Krembil Centre for Neuroinformatics at the Centre for Addiction and Mental Health in Toronto, Canada. He is also titular professor at Ecole Polytechnique Fédérale de Lausanne, Switzerland. His background is in Computational Neuroscience and following post-doctoral studies in San Diego and Wisconsin, he joined the Computational Biology team at IBM Research. He has led the development of multiple large-scale neuroinformatics infrastructures and initiatives, in the Blue Brain Project, European Human Brain Project, and served as the Executive and Scientific Director of the International Neuroinformatics Coordinating Facility in Stockholm. His research is focused on the cellular basis of brain states, with a focus on thalamocortical circuitry. He has developed numerous large-scale models of cortical and corticothalamic systems during wakefulness, sleep and anesthetic conditions, which have contributed to our understanding of the cellular and synaptic mechanisms underlying diverse brain states.



Dr Petr Holub

Associate Professor of computer science, Masaryk University

Dr. Holub is Associate Professor of computer science at Masaryk University. Since 2015, he has become Senior IT and Data Protection Manager with BBMRI-ERIC, European Research Infrastructure Consortium for Biobanking and BioMolecular Resources. He is also Chief Information Technology Officer for BBMRI-ERIC Common Service IT. He has background both in sciences and computer sciences. He was head of the Department of Communication Technologies at Institute of Computers Science, Masaryk University, as well as architect of advanced multimedia and collaborative systems of the Czech national e-infrastructure at CESNET. His research in computer networks and multimedia processing has led to more than 50 research papers in established computer science, bioinformatics and medical informatics journals and ranked conferences. He has received Best Open-Source Software Award by ACM Multimedia SIG. He is a co-founder of Comprinato company, which commercializes research results in acceleration of compression algorithms.



Drew Holzapfel

Executive Director
of The Global
CEO Initiative on
Alzheimer's Disease
(CEOi)


Drew Holzapfel serves as the Executive Director of The Global CEO Initiative on Alzheimer's Disease (CEOi), a coalition of leading corporations investing in Alzheimer's disease research, treatment and care. He is also the Secretariat for the Davos Alzheimer's Collaborative, a multi-year initiative initiated by CEOi and The World Economic Forum in 2020. Drew is a Managing Partner at High Lantern Group. Over the course of his career, Drew has held positions in the federal government and with pharmaceutical companies, including Pfizer, The White House and US Department of Health and Human Services. As a Managing Partner at High Lantern Group, he opened the firm's Philadelphia office and has led the firm's work with top biopharmaceutical companies to drive market readiness, position key policy issues, build partnerships and gain third-party organization support. He also has helped many nonprofit/disease advocacy organizations and coalitions develop their positioning strategies and strengthen their influence and impact. Drew earned his Bachelor's degree from Emory University and a Master's of Business Administration from The University of Maryland.



Professor Takeshi Iwatsubo

Professor of
Neuropathology at the
School of Medicine,
University of Tokyo

Originally trained as a neurologist and neuropathologist, Dr Iwatsubo has contributed to the studies of human neurodegenerative disorders, especially Alzheimer's and Parkinson disease, using multidisciplinary approaches. He demonstrated that A β 42 is the initially deposited species in senile plaque amyloid, elucidated the process of γ -secretase complex formation and identified hyperphosphorylated ω -synuclein as a component of Lewy bodies. On the clinical front, Iwatsubo has been the PI of Japanese AD Neuroimaging Initiative (J-ADNI) and currently he serves as the PI of the A4 study in Japan, and the Japanese Trial Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (J-TRC-PAD).



Inez Jabalpurwala

Global Director,
VINEx


Inez has extensive experience leading cross-sector collaborations with organizations in health research, academia, and international development. She is currently Global Director of VINEx, a non-profit venture initiated by Rocket Science Health, to understand how viruses may affect the central nervous system. She is the Founding and Former CEO and President of the Brain Canada Foundation (2001 to 2020). When she joined, the organization had about \$1 million in assets; over her tenure, Brain Canada grew to become the leading non-governmental funder of brain research in Canada, providing grants totaling \$250 million and involving more than 1,000 scientists and clinicians based at 115 institutions across Canada. To achieve these results, Inez managed multiple stakeholders, and secured more than 100 partnerships, including leading the approach for a \$160-million matching fund with the Government of Canada, and raising \$130 million from a range of donors, institutions and organizations.



Professor Yves Joannette

Professor of Cognitive
Neurosciences and
Aging at the Faculty
of Medicine at the
Université de Montréal

Yves Joannette is a Professor of Cognitive Neurosciences and Aging at the Faculty of Medicine at the Université de Montréal as well as Laboratory Director at the Research Center of the Centre de recherche de l'Institut universitaire de gériatrie de Montréal. He was recently appointed the first Director of the Consortium in Digital Health of the Université de Montréal. He was until recently the Scientific Director of the Institute of Aging of the Canadian Institutes of Health Research where he co-lead the Canadian Longitudinal Study on Aging, as well as the Dementia Research Strategy. Dr Joannette played a major role in bringing Canada as member of many international initiatives, including three European collaborative initiative. He also contributed to the World Health Organization efforts both in relation with the dementia global strategy as well as the global efforts in healthy ageing. Yves Joannette is Member and former Chair of the World Dementia Council.



Jonathan Kingsley


Senior Policy Advisor,
Office for Life Science,
Government of United
Kingdom



Professor Miia Kivipelto

Professor in Clinical
Geriatrics at
Karolinska Institutet
(KI)

Miia Kivipelto, MD, PhD, is Professor in Clinical Geriatrics at Karolinska Institutet (KI), Center for Alzheimer Research and senior geriatrician and Director for Research & Development of Medical Unit Aging at Karolinska University Hospital, Stockholm, Sweden. Part of her Nordic Brain Network multidisciplinary research team (around 100 researchers and clinical staff) is located at University of Eastern Finland and Imperial College London, UK, where she has part time position as Professor. Her frontline research findings have been published in leading journals (330+ publications, H-index 75) and she has received numerous prestigious awards. Dr. Kivipelto's translational research focuses on the prevention, early diagnosis and treatment of cognitive impairment, dementia and Alzheimer's disease (AD). Through epidemiological studies, Prof. Kivipelto has identified various lifestyle and vascular risk factors for dementia and interactions with genetic factors and clarified underlying mechanisms. She is the PI of the landmark FINGER trial and founder and scientific leader of World-Wide FINGERS network. Professor Kivipelto is often invited to leading global dementia conferences and task forces.



Professor Zoe Kourtzi

Professor of Computational Cognitive Neuroscience at the Department of Psychology, University of Cambridge


Zoe Kourtzi is Professor of Computational Cognitive Neuroscience at the Department of Psychology, University of Cambridge. Her research aims to develop predictive models of neurodegenerative disease and mental health with translational impact in early diagnosis and personalised interventions. Kourtzi received her PhD from Rutgers University and was postdoctoral fellow at MIT and Harvard. She was a Senior Research Scientist at the Max Planck Institute for Biological Cybernetics and then a Chair in Brain Imaging at the University of Birmingham, before moving to the University of Cambridge in 2013. She is a Royal Society Industry Fellow, Fellow and Cambridge University Lead at the Alan Turing Institute, and the Scientific Director for Alzheimer's Research UK Initiative on Early Detection of Neurodegenerative Diseases (EDoN).



Ivan Koychev

Clinical academic psychiatrist, University of Oxford

Ivan Koychev is a clinical academic psychiatrist at the University of Oxford with a focus on the development of treatments for neurodegenerative disorders. His research experience spans the key components of neuroscience clinical trial methodology: conduct of proof-of-concept (PoC) biomarker-based clinical trials in surrogate populations, testing of repurposed compounds, development of stratification and efficacy biomarkers and creation of infrastructure for large-scale stratified recruitment into preclinical dementia experimental medicine studies and clinical trials. He has a particular interest in the development of scalable biomarkers for the detection of preclinical Alzheimer's disease using digital technologies, blood biomarkers and longitudinal health data. Clinically, he works as a Consultant Neuropsychiatrist focusing on the assessment and management of patients with neuropsychiatric presentations in acute medical settings.



Dr Alix Lacoste

Vice President of Data Science, Blackfynn


Alix Lacoste, PhD, is currently the VP of Data Science at Blackfynn. Blackfynn combines data, technology, and domain expertise to bring clinical-stage therapeutics to patients with neurodegenerative diseases, starting with Parkinson's. Prior to Blackfynn, Alix was the VP of Data Science at BenevolentAI, where she led a team responsible for developing machine learning and data science technologies to improve and evaluate the drug discovery pipeline. Alix started her industry career at IBM Watson Health, where she led research projects in drug discovery with academic and pharma partners. Alix has presented her work in both biomedical and machine learning journals and conferences.



Dr John Langton

Chief Technology Officer (CTO) of Linus Health

John T. Langton is the Chief Technology Officer (CTO) of Linus Health where he drives the technology strategy to deliver next generation solutions for neurological health. Prior to joining Linus, John supported a diverse product portfolio at Wolters Kluwer including applications that engage millions of patients in multi-model, digital experiences to optimize patient engagement as well as health outcomes. Before joining Wolters Kluwer, John led the data science team at athenahealth which applies machine learning algorithms to electronic medical records for over 40 million patients. He has a wealth of experience designing enterprise infrastructure that can process health data at scale while addressing privacy and security concerns. He is an expert in artificial intelligence and has a great breadth of expertise in software design and delivery. John holds a Ph.D. in computer science from Brandeis University and is a frequent speaker on topics related to healthcare, cybersecurity, and advanced technology.



Professor Allan Levey

Professor and Chair of the Department of Neurology at Emory University


Dr. Allan Levey is Professor and Chair of the Department of Neurology at Emory University and Director of the Goizueta Alzheimer's Disease Research Center. Dr. Levey is a neurologist and neuroscientist internationally recognized for his work in neurodegenerative disease, with more than 400 research publications. His work in Alzheimer's Disease and related neurodegenerative disorders has contributed to understanding mechanisms involved in these conditions and translation to new therapeutic strategies and biomarkers. He leads multi-institutional teams in NIH translational programs, including Accelerating Medicine Partnership for Alzheimer's Disease and the TREAT-AD consortia. He currently serves as Co-Chair of the Department of Health and Human Services National Alzheimer's Project Act (NAPA) Advisory Council on Alzheimer's Research, Care and Services and Chair of the Clinical Task Force for the NIA Alzheimer's Disease Research Center program.



Dr Rebecca Li

Executive Director of Vivli and on faculty at the Center for Bioethics at the Harvard Medical School

Rebecca Li, PhD, is the Executive Director of Vivli and on faculty at the Center for Bioethics at the Harvard Medical School. Previous to her current role she was the Executive Director of the MRCT Center of Brigham and Women's Hospital and Harvard for over 5 years and remains a Senior Advisor at the Center. She has over 25 years of experience spanning the entire drug development process with experience in Biotech, Pharma and CRO environments. She completed a Fellowship in 2013 in the Division of Medical Ethics at Harvard Medical School. She earned her PhD in Chemical and Biomolecular Engineering from Johns Hopkins University.



Dr I-Chun Lin

Scientific Officer, UK
Dementia Research
Institute


I-Chun joined the UK Dementia Research Institute (UK DRI) in September 2019 as Scientific Officer, contributing to the development of institute-wide scientific and training initiatives, strategic partnerships and reporting. She coordinates the UK DRI's data science and informatics efforts. I-Chun holds a MSci degree in Natural Sciences from the University of Cambridge and a PhD in Computational Chemistry from EPFL. Her postdoctoral research experience spanned from computational chemistry to systems neuroscience, focusing on describing complex, high-dimensional systems using mathematical models. Before joining UK DRI, she studied coordinated activity of neuronal populations in the visual system, performing large-scale electrophysiological recordings with optogenetics as well as the subsequent analysis and computational modelling.



Professor Simon Lovestone

Professor of
Translational
Neuroscience at
Oxford University

Prior to his current role, Simon Lovestone was Professor of Translational Neuroscience at Oxford University where with Chas Bountra he founded the Alzheimer's Research UK Drug Development Institute. Before this he spent close to 25 years at King's College London and the Maudsley Hospital including leading the NIHR Biomedical Research Centre for Mental Health and being Director of R&D for King's Health Partners, an Academic Health Sciences Centre. His research interests are in the mechanisms of Alzheimer's Disease and in the search for biomarkers and building on these, in drug discovery and experimental medicine. He studied Microbiology at Sheffield University and then Medicine at Southampton University followed by an MPhil in Psychiatry and a PhD in Neuroscience from the University of London. He was knighted for services to Neuroscience research in 2017.



Professor Ronan Lyons

Associate Director
for the Dementias
Platform UK (DPUK)


Ronan Lyons, MD, is an epidemiologist and public health physician who trained and worked in Ireland before moving to the UK in 1992 where he has played a leading role in the development of population data science. He is Professor of Public Health at Swansea University Medical School and Research Director and national lead for population health research with Health Data Research UK. He serves as Associate Director for the Dementias Platform UK (DPUK) where he is responsible for the Data Portal which provides for globally accessible analysis to multimodal data on more than three million participants from many research cohorts, generating new insights into ageing, diseases and dementia risk. DPUK is a public-private partnership funded by the UKRI Medical Research Council which aims to detect and treat dementia earlier than ever before.



Dr Husseini Manji

Global Head,
J&J Science for Minds

Husseini K Manji, MD, FRCPC is Global Head, J&J Science for Minds, and immediate past Therapeutic Head for Neuroscience at Janssen Research & Development, one of the Johnson & Johnson pharmaceutical companies. His research has investigated disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. This has led to the FDA approval of the first novel antidepressant mechanism (NMDA-antagonism) in decades and has been actively involved in developing biomarkers to help refine these diseases. Dr Manji has been inducted into the National Academy of Medicine, the World Economic Forum Global Future Councils and is a member of Harvard/MIT's Stanley Center SAB, amongst other appointments. He has received a number of awards including the NIMH Director's Career Award for Significant Scientific Achievement, and has published extensively on the molecular and cellular neurobiology of severe neuropsychiatric disorders and development of novel therapeutics with over 300 publications in peer-reviewed journals, including Science and Nature Neuroscience.



**Professor
Maryann
Martone**

Professor Emerita,
UCSD


Maryann Martone received her BA from Wellesley College in Biological Psychology and Ancient Greek and her Ph. D. in Neuroscience from the University of California, San Diego. She is a professor Emerita at UCSD, but still maintains an active laboratory, the FAIR Data Informatics Lab. She started her career as a neuroanatomist, specializing in light and electron microscopy, but her main research for the past 20 years focused on informatics for neuroscience, i.e., neuroinformatics. She led the Neuroscience Information Framework (NIF), a national project to establish a uniform resource description framework for neuroscience, and the NIDDK Information Network (dknet), a portal for connecting researchers in digestive, kidney and metabolic disease to data, tools, and materials. Dr. Martone is past President of FORCE11, an organization dedicated to advancing scholarly communication and e-scholarship and served as Editor-in-Chief for Brain and Behavior for five years.



**Dr Eliezer
Masliah**

Director of the
Division of
Neurosciences,
NIA/NIH

Dr Masliah joined the NIA/NIH as Director of the Division of Neurosciences in the summer of 2016. before joining NIA he held joint appointments as tenured track Professor at the Departments of Neurosciences and Pathology and as Director of the Autopsy Service at UCSD. As head of UCSD's Experimental Neuropathology Laboratory, he investigated mechanisms of synaptic damage in AD, PD and other neurodegenerative disorders, was involved with the discovery of α -synuclein and developed novel models as well as new gene experimental immunotherapies. Four of the experimental therapeutic approaches developed at his laboratory targeting α -synuclein have now passed Phase I clinical trials. He is the author of over 800 original research articles, 70 book chapters and dozens of patents.



Dr Marilyn Miller

National Programme
Director Genetics of
Alzheimer's Disease,
Institute on Aging
(NIA)


Marilyn Miller, Ph.D., began as Program Director for the Genetics of Alzheimer's Disease, Tau, and Hormone Research portfolios at the National Institute on Aging (NIA) in 2000. As Program Director for the Genetics of Alzheimer's Disease, a major component of her portfolio is the Alzheimer's Disease Sequencing Project (ADSP). The ADSP is an initiative announced in 2012 to fight Alzheimer's disease (AD). The Project emphasizes generation and analysis of sequence data from large AD cohorts including several diversity sample sets and a large family based study. The Project includes two major AD genetics consortia, the NIA Genetics of Alzheimer's Disease Data Storage Site (NIAGADS); the Genomics Center for Alzheimer's Disease at the University of Pennsylvania; the National Cell Repository for Alzheimer's Disease (NCRAD); several large scale sequencing centers; a collaboration with IBM-Watson; and numerous cooperative agreements that fund all Phases of the ADSP.



Professor Sean Mooney

Chief Research
Information Officer
(CRIO) of UW Medicine

Dr. Sean Mooney is the Chief Research Information Officer (CRIO) of UW Medicine, the Director of Informatics for the Institute of Translational Health Sciences and a Professor in the Department of Biomedical Informatics and Medical Education at the University of Washington. As CRIO, he leads the growing Research Information Technology team that contributes to a number of national research networks including the Center for Data To Health, N3C, the National Kidney Precision Medicine Project, the National Alzheimer's Coordinating Center, the UW Clear Center and others. Currently he is focusing on developing an Epic Research team for supporting research in the EHR at UW Medicine and supporting a Medical Data Science initiative for UW. He was trained at UCSF (PhD) and Stanford (Postdoc) and has previously been appointed as faculty at Indiana University and the Buck Institute.



Jillian Oderkirk

Senior Health
Economist in the
Health Division, OECD

Jillian Oderkirk is a Senior Health Economist in the Health Division of the Organisation for Economic Co-operation and Development (OECD) in Paris, France. Jillian studies OECD countries' progress in advancing national health information infrastructure including the development of electronic health record systems, adoption of digital technologies and health data governance. Prior to joining the OECD in 2011, Jillian was Director, Health Analysis Division at Statistics Canada in Ottawa, Canada. Jillian has a Master's Degree in economics from McMaster University, Hamilton, Canada.



Corinne Pasquay

Charge de mission, Pole
ARS Sante, Secretariat
general


A former student of the National School of Public Health, C Pasquay worked for 7 years as a hospital director. After his training at ENA, C Pasquay worked in various ministries. She is currently in charge of steering the ministerial roadmap for neurodegenerative diseases and as such secretary of the scientific committee of the BNA (French national data Alzheimer base).



Dr Maria Quinton

Director in
Neuroscience
Translational
Medicine at Takeda
Pharmaceuticals

Maria Quinton, PhD, is a Director in Neuroscience Translational Medicine at Takeda Pharmaceuticals where she develops and implements molecular biomarker strategies for preclinical and clinical projects. Dr. Quinton received her PhD in Pharmacology from Louisiana State University in 2004 prior to her post-doctoral fellowship at Boston University. From 2007-2014, Dr. Quinton worked at Sunovion pharmaceuticals, where she led discovery projects and supported programs with neurochemistry, neuropharmacology and translational studies. Before joining Takeda in 2018, she held translational Neuroscience roles at Retrophin, AstraZeneca, and Rodin Therapeutics, supporting programs in rare diseases, psychiatric, neurodevelopmental, and neurodegenerative disorders.



**Dr Tim
Raemaekers**

Programme Officer
Neurodegeneration,
European Commission
(EU)



Currently contributing to policy development in the neuroscience area, as well as in the management of a number of neuroscience-related projects. Previous experience in working together with other European Commission departments, national Competent Authorities and stakeholders to develop and improve new tools for a coherent, safe and effective management of medical devices within Europe. Additional experience in acquiring external funds for strategic and applied research, as well as in valorising research results (technology transfer). Further experience in methods to facilitate translational research, as well as in research communication and the coordination of scientific events.



**Professor
Vijayalakshmi
Ravindranath**

Professor, Centre for
Brain Research

Dr. Vijayalakshmi Ravindranath obtained her Ph.D from the University of Mysore in 1981. In 1986, after completing her post-doctoral training at the National Institutes of Health, USA, she joined the Department of Neurochemistry at National Institute of Mental Health and Neurosciences, (NIMHANS) Bangalore. In 1999, the Dept. of Biotechnology (DBT), Government of India sought her out to help establish the National Brain Research Centre (NBRC), an autonomous institution of DBT, Ministry of Science and Technology as a centre of excellence and to co-ordinate and network neuroscience research groups in the country. She continued as Founder Director, NBRC till May 2009, when she returned to Bangalore at the Indian Institute of Science (IISc) as Professor and Founder Chair of the newly created Centre for Neuroscience. She is currently Founder Director, Centre for Brain Research (CBR) at Indian Institute of Science. The newly established Centre for Brain Research is a unique public-private partnership between IISc (a public funded institution) and Pratiksha Trust (a philanthropy) that funds CBR. Research at CBR is focused on aging brain and a large, prospective longitudinal study of 10,000 ageing individuals has been initiated for the first time in India. In addition, she has received generous funding from Tata Trusts, which has paved the way for starting a longitudinal study in an urban cohort.



Dr Adam Resnick

Director for Neurosurgical Translational Research, and Alexander B. Wheeler Endowed Chair in Neurosurgical Research at Children's Hospital of Philadelphia


Adam Resnick, PhD, is a research scientist in the Department of Biomedical and Health Informatics, Director for Neurosurgical Translational Research, and Alexander B. Wheeler Endowed Chair in Neurosurgical Research at Children's Hospital of Philadelphia (CHOP). Dr. Resnick is also Co-Director of the Center for Data Driven Discovery in Biomedicine (D3b) at CHOP, leading a multidisciplinary team to build and support a scalable, patient-focused healthcare and educational discovery ecosystem on behalf of all children. Dr. Resnick's research focuses on defining the cell signaling mechanisms of oncogenesis and tumor progression in brain tumors, to elucidate the molecular and genetic underpinnings of each tumor in an effort to identify and develop targeted therapies. Dr. Resnick serves as Scientific Chair for the Children's Brain Tumor Tissue Consortium and Pacific Pediatric Neuro-Oncology Consortium, which include over 20 pediatric hospitals worldwide. He is also Principal Investigator for the Gabriella Miller Kids First Data Resource Center.



Professor Craig Ritchie

Professor of Psychiatry of Ageing, University of Edinburgh

Craig Ritchie is the Professor of Psychiatry of Ageing at the University of Edinburgh. His research interest is in the association between mid life risks of neurodegenerative disease and their phenotypic expression. This work will help uncover early disease mechanisms and therein potential for both pharmacological and non-pharmacological interventions. He is Chief Investigator on both the PREVENT Dementia and European Prevention of Alzheimer's Dementia Programmes. Most recently he established with partners in Alzheimer Scotland and Scottish Government 'Brain Health Scotland' which seeks to translate the emerging individual and population level research into a newly established national network of Brain Health Clinics and Public Health Policy respectively. He is also the Chairperson of the Scottish Dementia Research Consortium.



Professor Louise Robinson

Professor of Primary Care and Ageing, Newcastle University


Professor Dame Louise Robinson, is an academic GP and Professor of Primary Care and Ageing at Newcastle University. She was the first GP to be awarded a prestigious NIHR Professorship. Professor Robinson also holds the first UK Regius Professorship in Ageing. Louise leads a research programme focused on improving quality of life and quality of care for older people, especially those with dementia. She leads 1 of only 3 Alzheimer Society national Centres of Excellence on Dementia Care. Louise was primary care lead for the Prime Minister's Dementia Challenge and is a member of the National Dementia Care Guidelines development group.



Dr Klaus Romero

Chief Science Officer, C-Path

Klaus Romero MD, MS, FCP is a clinical pharmacologist and epidemiologist by training, with 17 years combined experience in clinical research. Dr. Romero has been with C-Path since December of 2007, and during his tenure, he established C-Path's Quantitative Medicine Program, which has led clinical pharmacology, pharmacoepidemiology and modeling and simulation projects in Alzheimer's disease, polycystic kidney disease, tuberculosis, type 1 diabetes, Parkinson's disease, Duchenne muscular dystrophy, kidney transplantation and Huntington's disease, achieving major milestones such as the first regulatory endorsement by FDA and EMA of a clinical trial simulation tool for mild and moderate Alzheimer's Disease and the qualification of an imaging prognostic biomarker for PKD. He is a fellow of the American College of Clinical Pharmacology and the American Society for Clinical Pharmacology and Therapeutics, as well as a founding member of the International Society of Pharmacometrics.



Dr Jane Roskams

Professor of
Neuroscience, Centre
for Brain Health,
University of British
Columbia


Jane Roskams is a respected leader in brain open science, collaborating broadly to build new routes to data-driven impact, at the interface of neuroscience and mental health sciences. Originally trained in AD Neuropathology and Genetics at Johns Hopkins, for over two decades she led a research team at the University of British Columbia (UBC) focused on brain repair after injury - and in progressive neurodegenerative disease (AD, MS, ALS). Recently, she served as Executive Director of the Allen Institute, and Brain Commons – a cloud-hosted aggregation of multiple data types (academic, clinical, governmental, military, and non-profit) to accelerate discovery in PTSD and TBI. She co-leads the Exec of the Canadian Open Neuroscience Platform (CONP), a new interoperable platform combining neurological and neuropsychiatric disorder data with accessible analytical tools, ethics toolkits and online publishing (Neurolibre). At the INCF, she has led the development of an open online Training Space - delivering analytics and FAIR data training for brain discovery globally.



Professor Martin Rossor

NIHR National
Director for Dementia
Research, UCL Queen
Square Institute of
Neurology

Martin Rossor is the NIHR National Director for Dementia Research, Professor Emeritus, and Principal Research Associate at the UCL Queen Square Institute of Neurology. Following his training in clinical neurology at the National Hospital, Queen Square, Martin undertook primary research on the neurochemistry of degenerative dementia at the MRC Neurochemical Pharmacology Unit, Cambridge, before being appointed as Consultant Neurologist at St. Mary's Hospital London and the National Hospital in 1986. Martin was appointed as the Chairman of the Division of Neurology in 2002, after becoming Professor of Clinical Neurology. He established a specialist cognitive disorders clinic, which acts as a tertiary referral service for young onset and rare dementias. Martin's clinical research interests are in the degenerative dementias, particularly familial disease, and more recently in general cognitive impairment in systemic disease and multimorbidity.



Professor James Rowe

Professor of Cognitive Neurology and Director of Cambridge Centre for Frontotemporal Dementia and Related Disorders, University of Cambridge


As Professor of Cognitive Neurology, James Rowe studies the mechanisms and potential treatments for frontotemporal dementia, Progressive Supranuclear Palsy and Alzheimer's disease. He trained in medical sciences and experimental psychology at Cambridge, before clinical studies in Oxford and his PhD at the Institute of Neurology, London. After further specialist training in Copenhagen, he returned to Cambridge in 2005. He is Associate Director of DPUK, leading the academic-industrial partnership for experimental medicine. He leads the Centre for Frontotemporal Dementia and the Clinical program within the Centre for Parkinson-plus, together with regional NHS clinics for these disorders. The integration of multimodal brain imaging, genetics, pharmacology and computational modelling provides a powerful platform to understand neurological disease, and to assess the efficacy of novel treatments.



Dr Laurie Ryan

Chief of the Clinical Interventions and Diagnostics Branch in the Division of Neuroscience, National Institute on Aging (NIA)

Dr. Laurie Ryan is Chief of the Clinical Interventions and Diagnostics Branch in the Division of Neuroscience at the National Institute on Aging, part of the NIH. She oversees the development, coordination, and implementation of the division's clinical therapeutic and diagnostics research programs and infrastructure. Dr. Ryan also directs the Alzheimer's disease and related dementias pharmacological clinical trials research portfolio. Dr. Ryan received her BA in Human Development from St. Mary's College of Maryland in 1986 and her Masters in Psychology from Loyola College in Maryland in 1991. She undertook doctoral training in clinical psychology with specialty focus in neuropsychology at Louisiana State University in Baton Rouge. She completed a neuropsychology-focused psychology residency at the Medical University of South Carolina, Charleston and clinical neuropsychology fellowship at Thomas Jefferson University, Philadelphia.



Nadeem Sarwar

Founder & President,
Eisai Center for
Genetics Guided
Dementia Discovery
(G2D2)


Nadeem's expertise stems from the intersection of genomics and data sciences with collaborative business models for therapeutic discovery. He is the Founder and President of the Eisai Center for Genetics Guided Dementia Discovery (G2D2), with past executive experience in academia (Tenured Faculty, University of Cambridge), big-pharma (Senior Director, Pfizer), mid-sized pharma (VP, Eisai), and Biotech (G2D2).



Dr Joachim Schultze

Founding Director of
Systems Medicine at
the German Center
for Neurodegenerative
Diseases (DZNE)

Joachim L. Schultze is Founding Director of Systems Medicine at the German Center for Neurodegenerative Diseases (DZNE) and Founding Director of the PRECISE Platform for Single Cell Genomics and Epigenomics at the DZNE and the University of Bonn. He went to Medical School in Tübingen, spent 10 years at Dana-Farber Cancer Institute, Harvard Medical School, in Boston before he returned to Germany with a Sofia Kovalevskaya Award of the Humboldt Foundation. He is the coordinator of the German DFG-funded NGS competence centers in Germany and speaker of the West German Genome Center at the Bonn site. He contributes his expertise to several EU consortia. He is an expert in macrophage biology and works at the interphase between immunology, genomics and the computational sciences. With his team he was the first to apply memory driven computing and Swarm Learning to medical research. His goal is to bring single cell technologies and machine learning approaches to the clinical arena. He is leading several programs on applying single cell technologies, memory driven computing and Swarm Learning to patients with Alzheimer's disease, chronic obstructive pulmonary disease, lung cancer or HIV. He has established research collaborations with HPE, Comma Soft, Boehringer Ingelheim, Becton Dickinson and other companies.



**Professor
Gustavo Sevlever**


Professor of Pathology,
FLENI (Argentina)



Dr David Sibbald

CEO, Aridhia

David is the CEO of Aridhia, a health data science company which he founded in 2008. Aridhia provides a cloud-based data discovery and analysis platform (the Aridhia Digital Research Environment). The Aridhia DRE is used globally by leading healthcare, academic and philanthropic organisations for data sharing and bio-medical data science initiatives across neuro-degenerative, oncology and infectious disease programs. Previously he was the Co-Founder, Chairman and CEO of Atlantech Technologies, a communications software company which he founded in 1992 and sold to Cisco Systems in March 2000. He was the Founder and CEO of Sumerian, a data analytics company he founded in 2002 and sold to ITRS. David is the Founder and Trustee of the Kate MacAskill Foundation, a charitable organisation providing education, care and micro-enterprise funding for children and young adults in the developing world. He has been awarded honorary doctorates from Glasgow University, Glasgow Caledonian University, the University of Paisley and the University of Strathclyde for services to Scottish science and philanthropy. He is a Fellow of the Royal Society of Edinburgh, Scotland's National Academy of Science and Letters. In the 2010 New Year Honours List, David was awarded an OBE for charitable services in Scotland and overseas.



Dr Sudhir Sivakumaran

Vice President of the Neuroscience Program, Executive Director for the Critical Path for Alzheimer’s Disease (CPAD)


Sudhir Sivakumaran, PhD, serves as the Vice President of the Neuroscience Program, Executive Director for the Critical Path for Alzheimer’s Disease (CPAD) consortium, and the Interim Executive Director for the Huntington’s Disease Regulatory Science Consortium (HD-RSC) at The Critical Path Institute (C-Path). Dr. Sivakumaran oversees the overall strategic planning, management and execution of the strategic objectives and goals of the Neuroscience Program and the individual consortia. Dr. Sivakumaran also leads the C-Path Industry Data Sharing Initiative aimed at acquisition and management of CDISC standardized high-relevance clinical trial and observational study datasets in Alzheimer’s disease. Together with the Quantitative Medicine Program at C-Path, Dr. Sivakumaran leads our efforts in the generation of novel regulatory-endorsed drug development tools (DDTs) by fostering relationships and engagement with industry, regulatory agencies (FDA, EMA) and patient advocacy organizations.



Dr Saskia Sivananthan

Chief Research and KTE Officer at the Alzheimer Society of Canada

Dr. Saskia Sivananthan, an internationally recognized strategy and policy advisor on dementia care, is the Chief Research and KTE Officer at the Alzheimer Society of Canada. She oversees the Alzheimer Society Research Program, a dementia research priority setting leader and the only research funder who engages people living with dementia in all aspects of research. Previously, Dr. Sivananthan served as a senior strategy and policy advisor consulting for the World Health Organization (WHO) on its overall global dementia strategy. Dr. Sivananthan co-drafted the WHO’s Global Action Plan on the Public Health Response to Dementia which was unanimously adopted at the 170th World Health Assembly by all 194 member-states. It identified key priorities and established international goals to fight stigma and advance dementia care. Dr. Sivananthan is a neuroscientist and health data scientist.



Dr Heather Snyder

Vice president, Medical & Scientific Relations at the Alzheimer's Association

Heather M. Snyder, Ph.D., is vice president, Medical & Scientific Relations at the Alzheimer's Association®. In this role, she oversees Association initiatives that accelerate innovative Alzheimer's research and provide opportunities for the global dementia community to connect and collaborate. Dr. Snyder is responsible for the progress the Association has made in Alzheimer's and dementia research funding. To increase knowledge about prevention and risk reduction, Dr. Snyder serves on the executive team for the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER). She holds a Ph.D. in molecular biology from Loyola University Chicago Stritch School of Medicine and a bachelor's degree in biology and religious studies from the University of Virginia.



Dr Lucy Stirland

Clinical Lecturer in Old Age Psychiatry, University of Edinburgh,


Lucy Stirland is a Clinical Lecturer in Old Age Psychiatry in Edinburgh, UK. In 2020, she completed her PhD on the epidemiology of mental and brain health in multimorbidity. She is finishing her clinical training alongside further research using routinely collected healthcare data to link polypharmacy and dementia outcomes.



Dr Elina Suzuki

Advisor to the Director of Employment, Labour and Social Affairs, OECD

Elina Suzuki is an Advisor to the Director of Employment, Labour and Social Affairs at the Organisation for Economic Co-operation and Development in Paris. Her work focuses primarily on dementia, ageing, long-term care, and the use of new digital tools for health. She co-authored the recent OECD report Care Needed: Improving the Lives of People with Dementia, which presents the most up-to-date and comprehensive cross-country assessment of the state of dementia care in OECD countries. Prior to joining the OECD, Elina worked at SEEK Development in Berlin. She graduated from McGill and Harvard.



Dr Paweł Świeboda

Director General,
Human Brain Project


Paweł Świeboda is Director General of the Human Brain Project, one of the largest research programmes in the world in the area of brain science. He is also CEO of EBRAINS AISBL, in charge of building the EBRAINS Research Infrastructure for the study of the brain. Prior to joining the HBP and EBRAINS, he was Deputy Head and Head of Research of the European Political Strategy Centre at the European Commission. He had also served on the European Commission's Sounding Board on the EU's Science, Research and Innovation Performance and the Global Agenda Council on Europe of the World Economic Forum.



LiYu Tang

Secretary General
and co-founder of the
Taiwan Alzheimer's
Disease Association
(TADA)

Li-Yu Tang is Secretary General and co-founder of the Taiwan Alzheimer's Disease Association (TADA), and is a member of the Long-Term Care Committee of the Executive Yuan of Taiwan. She has over 28 years' experience in dementia research, practice and training. While at TADA, Li-Yu Tang has set up a toll-free helpline service, caregiver support groups and training programmes and a national dementia social support centre. She has created health promotion programmes for people with dementia and their care givers and provided training and coaching to more than sixty organisations throughout the country to help them deliver the programmes. She is also a consultant to Taipei City Government and is a member of a long-term care committee of four city governments in Taiwan.



**Dr Toshihisa
Tanaka**



Senior Specialist for
Dementia, Health and
Welfare Bureau MHLW,
Government of Japan



**Dr Maarten
Timmers**

Senior Director,
Science for Minds,
Johnson & Johnson

Maarten joined Janssen in 2005 and has been Head Clinical Scientists, Experimental Medicine Neuroscience until transitioning late 2020 to J&J's Science for Minds (SfM). SfM is an externally facing enterprise to bring together the three pillars of science, innovation, and society to build a creative, inclusive, and open research culture to make a major difference for our patients worldwide. SfM focusses on three key areas: 1) Alzheimer's disease 2) serious mental health disorders, particularly those affecting our youth; and 3) the development of holistic models, embracing digital technologies, to support these goals and fundamentally alter how we study, diagnose, and treat these disorders. Maarten holds a MSc in Biomedical Sciences (Free University Brussels), a postgraduate degree in Translational Medicine (University Edinburgh), a business degree from Vlerick International Business school and a PhD in Biomedical Sciences (University Antwerp). He holds leadership positions in several professional organizations and (co-)authored over 50 publications.



Professor Arthur Toga

Provost Professor of Ophthalmology, Neurology, Psychiatry and the Behavioral Sciences, Radiology and Biomedical Engineering, and Director of the USC Mark and Mary Stevens Institute of Neuroimaging and Informatics


Arthur W. Toga, Ph.D., is Provost Professor of Ophthalmology, Neurology, Psychiatry and the Behavioral Sciences, Radiology and Biomedical Engineering, and Director of the USC Mark and Mary Stevens Institute of Neuroimaging and Informatics. One of the world's leading authorities on neuroimaging, informatics, AI applications in neuroscience, mapping brain structure and function, and brain atlasing. Dr. Toga's research focus is in neurodegenerative disease and specifically works on Alzheimer's disease. His interdisciplinary work led to the creation of the Laboratory of Neuro Imaging (LONI), which he also directs and is one of the most advanced multidisciplinary neurological research centers in the world serving numerous multisite neuroscience projects from around the world. Funded by National Institutes of Health (NIH) grants as well as industry partners, LONI houses one of the largest computing facilities and largest brain image repository in the world.



Dr Maria Tome

Senior Scientific Officer at the Product Development and Scientific Support Department of the European Medicines Agency (EMA)

Dr. Tome serves as Senior Scientific Officer at the Product Development and Scientific Support Department of the European Medicines Agency (EMA). EMA can provide medicine developers advice on the most appropriate way to generate robust evidence on a medicine's benefits and risks. EMA provides scientific advice and qualification of novel methodologies to support the timely and sound development of high-quality, effective and safe medicines, for the benefit of patients.



Dr Elisabetta Vaudano

Principal Scientific Manager and portfolio manager for the neuroscience area at the Innovative Medicines Initiative (IMI)


Elisabetta Vaudano is Principal Scientific Manager and portfolio manager for the neuroscience area at the Innovative Medicines Initiative (IMI) the largest European Public Private partnership in Health Sciences (budget > 5 billion EUR). Elisabetta is Italian, trained in Italy and UK and worked thereafter in UK, Sweden, Denmark and Belgium. Elisabetta is a doctor in veterinary medicine, a PhD in neuroscience and an MSc in Laboratory Animal Science. Elisabetta has a solid scientific background acquired in the 10years she worked as scientist in prestigious academic institutions in England and Scandinavia. Elisabetta has also large experience R&D and in scientific management in the private sector, via a series of positions at increasing level of responsibility in the pharma industry and in biotech in Denmark. Elisabetta joined IMI in 2010 and has a deep experience in alliance management, stakeholder engagement across the public-private spectrum, fostering and setting up of public-private partnerships, management of complex and large international research consortia and last but not least on funding mechanisms and processes and administration of European Research programmes.



Octavio Vergara

National Director of SENAMA, Government of Chile


Octavio Vergara is a lawyer from Pontificia Universidad Católica de Chile and has a Master's degree in Public Administration & Management from the University College of London. Also, he has diplomas in Social Gerontology and in Prevention Approaches to Elder Abuse. Mr. Vergara also holds academic training specialization in strategic leadership, impact evaluation methods of social programs, and administrative regulation. He has developed his working career in elderly, both in the public and private sector. Under the first term of President Sebastián Piñera, he served as Chief of Staff of the National Service for the Elderly (SENAMA) between 2013 and 2014. Before assuming as National Director of SENAMA in 2018, he was Executive Director of Oportunidad Mayor Foundation, whose objective was to articulate and execute initiatives that promote active aging and comprehensive care for older people in Chile.



Dr Pieter Visser

Clinical epidemiologist at the Maastricht University Medical Centre and VU University Medical Center


Pieter Jelle Visser, MD, PhD, is a clinical epidemiologist at the Maastricht University Medical Centre and VU University Medical Center in the Netherlands and visiting professor at the Karolinska Institute in Stockholm, Sweden. His research focuses on the pathophysiology, diagnosis, prognosis and treatment of predementia Alzheimer's disease. He supervises the RADAR-AD clinical study on digital biomarkers in AD. In addition, he has coordinated projects on datasharing and data pooling such as the Netherlands Consortium of Dementia Cohorts, EMIF-AD and the Amyloid Biomarker Study.



George Vradenburg

Co-Chair, Davos Alzheimer's Collaborative

George Vradenburg serves as Co-Chair of the Davos Alzheimer's Collaborative, a coalition focused on driving global scientific, business, policy and financial coordination in Alzheimer's preparedness, co-convened in January 2020 by the Global CEO Initiative on Alzheimer's Disease (CEOi) and the World Economic Forum. In this role, George provides general oversight and advocacy and works to ensure the Collaborative remains sustainable and action-oriented. George is the Chairman and Co-Founder of UsAgainstAlzheimer's (UsA2), a disruptive and catalytic force committed to stopping Alzheimer's by 2020. In 2011, the United States Secretary of the Department of Health and Human Services named George to serve on the National Alzheimer's Advisory Council on Research, Care and Services for the first-of-its-kind National Alzheimer's Strategic Plan. George received his B.A. from Oberlin College, magna cum laude, where he was elected to Phi Beta Kappa, and his J.D. from Harvard Law School, cum laude.



Professor Huali Wang

Professor and Chair for Clinical Research, Director of the Dementia Care and Research Center, and Associate Director of Beijing Dementia Key Lab, Peking University Institute of Mental Health


Dr Huali Wang is Professor and the Chair for Clinical Research, Director of the Dementia Care and Research Center, and Associate Director of Beijing Dementia Key Lab, Peking University Institute of Mental Health. She established the first dementia caregiver support group in China in 2000. Now she directs a training program for community doctors and service providers, and a train-the-trainer program for dementia caregivers support in China. She published five books on dementia care, including Smart Caregivers, China Memory Clinic Guideline and Practice Manual on Psychological Support for Older Adults. The care model has been partly adopted by WHO West Pacific Regional Office to develop the toolkit for community-based dementia care in low- and middle-income countries.



Dr Li-San Wang

Professor of Pathology and Laboratory Medicine and founding Co-Director of the Penn Neurodegeneration Genomics Center (PNGC) at the University of Pennsylvania


Li-San Wang, Ph.D., is Professor of Pathology and Laboratory Medicine and founding Co-Director of the Penn Neurodegeneration Genomics Center (PNGC) at the University of Pennsylvania. Dr. Wang's research integrates bioinformatics, genomics, and genetics to study neurodegeneration. He is PI of National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) and Co-Director of the Genome Center for Alzheimer's Disease (GCAD), both national initiatives in the United States to coordinate Alzheimer's genetics research, including Alzheimer's Disease Sequencing Project (ADSP) that will analyze genomic sequences of more than 30,000 individuals to find novel genetic variants linked to the disease.



Professor Caleb Webber

Chair, Informatics
Steering Committee,
UK Dementia Research
Institute


After obtaining his PhD from the European Bioinformatics Institute and Cambridge University, Caleb joined Oxford University contributing to almost all of the major large-scale genome projects. The group he established in Oxford in 2011 gained insights into complex neurological disorders using functional, integrative and network genomics, combined with statistical genetics and iPSC modelling. In 2018, he joined the UK Dementia Research Institute (UK-DRI) where his Programme generates and interprets large-scale molecular data sets from human tissue in order to identify genes and processes that contribute to many complex neurodegenerative disorders, and then validates findings within iPSC models. Within the UK-DRI, he leads the Bioinformatics Theme and chairs the Informatics Steering Committee.



Professor Michael Weiner

Professor in Radiology,
Medicine, Psychiatry
and Neurology,
University of California
San Francisco (UCSF)

Dr. Weiner has been conducting research for more than 50 years and is Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative (ADNI), and the BrainHealthRegistry.org, an internet-based registry with the overall goal of accelerating development of effective treatments for brain diseases. Dr. Weiner's research largely focuses on treatment to slow progression in Alzheimer's disease, and on early detection and prevention. Dr. Weiner completed his M.D at SUNY Upstate Medical Center Syracuse in 1965, his internship and residency at Mt. Sinai Hospital in 1967, and a residency and clinical fellowship in at Yale-New Haven Medical Center in 1968. He had various fellowships, earning Assistant Professorship at Stanford in 1974, and Associate Professorship at UCSF in 1980 when he was one of the first to perform MRS on an intact animal. He subsequently pursued development of MRI/MRS as a clinical tool. In 1983, he established the Magnetic Resonance Unit at the San Francisco VA Medical Center (which became the Center for Imaging of Neurodegenerative Diseases in 2000, and VA Advanced Imaging Research Center in 2020). Since 1990, he's been a Professor in Radiology, Medicine, Psychiatry and Neurology at UCSF.



Dr Alison Yao

Program Director in the Population Studies and Genetics Branch in the Division of Neuroscience, National Institute on Aging (NIA)

Alison Yao, Ph.D., is a Program Director in the Population Studies and Genetics Branch in the Division of Neuroscience. Dr. Yao oversees and directs research on functional genomics of Alzheimer’s disease and related dementias. Before joining NIA, Dr. Yao was a program officer at the National Institute of Allergy and Infectious Diseases (NIAID) for more than 10 years. During her tenure at NIAID, she developed and oversaw a number of genomics research programs, including functional genomics, structural genomics, bioinformatics, and genomic centers for infectious diseases. She was a co-lead for the NIH Data Science initiative on biomedical data indexing and discovery. Prior to joining NIAID, Dr. Yao was a staff scientist at Celera Genomics, where she developed algorithms for human genome annotation and contributed to projects in genome mapping and assembly, comparative genomics, and database design. Dr. Yao received her B.S. in genetics and M.S. in genetics from Wuhan University, China, and her Ph.D. in molecular genetics from the University of Guelph, Canada.



Dr Jennifer Yokoyama

Associate Professor, Memory and Aging Center, UCSF

Jennifer is a neurogeneticist studying genomic contributions in brain aging and disease. She earned her PhD at UCSF (2010), conducting genetic studies of behavior and neurological disease in dogs. As a postdoc at the UCSF Memory and Aging Center, Jennifer conducted neuroimaging and genetic studies of healthy cognitive aging and frontotemporal dementia. Jennifer joined the UCSF faculty in 2014. Now an Associate Professor, her Neurogenetics in Aging lab studies the effects of genotype on brain physiology, affect, behavior, and cognition in healthy older adults, and how this is related to increased vulnerability to (or protection from) neurodegeneration in diverse populations.

The World Dementia Council (WDC) is an international charity. It consists of senior experts and leaders drawn from research, academia, industry, governments and NGOs in both high-income and low- and middle-income countries, including two leaders with a personal dementia diagnosis. The WDC has an executive team based in London, UK.

worlddementiacouncil.org

© 2021 World Dementia Council
UK charity registration number: 1170743

Cover image editorial credit: Shutterstock.com

